HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.

You may also be interested in...



Sanofi Continues Consumer Health Trim, Sells Kaopectate US Rights To Arcadia

Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.

Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

Stada tells HBW Insight it remains on the lookout for deals despite only last month closing the acquisition of a basket of OTC brands from GSK. The German firm revealed its plans as it reported a double-digit rise in both sales and earnings at its Branded Products business for the opening six months of 2019.

European OTC Results Round-Up: Alliance Pharma, Boiron and Ipsen

UK-based Alliance Pharma reported a good year for its OTC business in 2018, while French players Boiron and Ipsen endured a more difficult 12 months.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122625

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel